Atlas Trials

A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer

Clinical trial NCT02225093 · COMPLETED

Trial details

NCT number
NCT02225093
Sponsor
Astellas Pharma Europe B.V.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Pharmacokinetics of DextromethorphanPharmacokinetics of CaffeineProstate Cancer
Start date
2013-10-02
Primary completion
2014-02-03
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.